Melinta Drug Patent Portfolio
Melinta owns 1 orange book drug protected by 15 US patents Given below is the list of Melinta's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12036219 | Methods of treating infections in overweight and obese patients using antibiotics | 02 Jun, 2034 | Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US7728143 | Salt and crystalline forms thereof of a drug | 19 Jun, 2031 | Active |
| US8497378 | Process for making quinolone compounds | 28 Dec, 2029 | Active |
| USRE46617 | Process for making quinolone compounds | 28 Dec, 2029 | Active |
| US8871938 | Process for making quinolone compounds | 23 Sep, 2029 | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8252813 | Salt and crystalline forms thereof of a drug | 02 Oct, 2026 | Active |
| US8273892 | Salt and crystalline forms thereof of a drug | 06 Aug, 2026 | Active |
| US8648093 | Salt and crystalline forms thereof of a drug | 07 Oct, 2025 | Active |
| US8969569 | Salt and crystalline forms thereof of a drug | 07 Oct, 2025 | Active |
| US9539250 | Salt and crystalline forms thereof of a drug | 07 Oct, 2025 | Active |
Latest Legal Activities on Melinta's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Melinta.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9539250 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8273892 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2024 | US8252813 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 May, 2023 | US9200088 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9750822 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9493582 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9200088 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US8410077 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US7635773 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Aug, 2022 | US8969569 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2022 | US8871938 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2022 | US8252813 |
|
Patent Term Extension Certificate
Critical
| 07 Mar, 2022 | US7728143 |
| Notice of Final Determination -Election Required | 08 Dec, 2021 | US8252813 |
Melinta's Family Patents
Melinta drugs have patent protection in a total of 26 countries. It's US patent count contributes only to 25.9% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Melinta Drug List
Given below is the complete list of Melinta's drugs and the patents protecting them.
1. Baxdela
Baxdela is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12036219 | Methods of treating infections in overweight and obese patients using antibiotics |
02 Jun, 2034
(9 years from now)
| Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(8 years from now)
| Active |
| US7728143 | Salt and crystalline forms thereof of a drug |
19 Jun, 2031
(6 years from now)
| Active |
| US8497378 | Process for making quinolone compounds |
28 Dec, 2029
(5 years from now)
| Active |
| USRE46617 | Process for making quinolone compounds |
28 Dec, 2029
(5 years from now)
| Active |
| US8871938 | Process for making quinolone compounds |
23 Sep, 2029
(4 years from now)
| Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US8252813 | Salt and crystalline forms thereof of a drug |
02 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8273892 | Salt and crystalline forms thereof of a drug |
06 Aug, 2026
(1 year, 8 months from now)
| Active |
| US8648093 | Salt and crystalline forms thereof of a drug |
07 Oct, 2025
(10 months from now)
| Active |
| US8969569 | Salt and crystalline forms thereof of a drug |
07 Oct, 2025
(10 months from now)
| Active |
| US9539250 | Salt and crystalline forms thereof of a drug |
07 Oct, 2025
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baxdela's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List